Northern Ireland

BRUSSELS, January 13, 2026 — Arnold & Porter announced today that Fabien Roy has joined the firm’s Life Sciences & Healthcare Regulatory practice as a partner, resident in Brussels. Niels Christian Ersbøll, head of Arnold & Porter’s Brussels office, said: “Fabien brings deep sector experience and technical acumen that enables him to help clients navigate complex EU regulatory frameworks. His reputation in Brussels for medical device and pharma regulatory matters, combined with his knowledge of artificial intelligence (AI) and data privacy issues, makes him an exceptional addition to our team.” Dan Kracov, chair of the firm’s Global Life Sciences Industry group, added: “Fabien’s arrival reinforces our ability to provide comprehensive regulatory counsel to life sciences companies wherever they do business. His knowledge of medical devices and emerging technologies, including AI-driven health solutions, will be invaluable as clients face increasingly complex compliance challenges around the globe.” Fabien advises life science technology companies on EU and international regulatory matters, with a focus on medical devices, diagnostics, and pharmaceuticals. He regularly counsels clients on AI-driven health technologies and Conformité Européenne marking of medical devices. Fabien also assists in addressing complex issues that arise during clinical studies, conformity assessment audits or inspections, and post-market activities. He is a qualified lead auditor for ISO 13485 quality management systems and regularly prepares, drafts, and reviews agreements related to clinical studies, registries, distribution, sponsor’s representatives, CROs, and European Authorized Representative Agreements. Fabien adds to the firm’s globally recognized medical device and technology practice, joining a team of 65 lawyers, including 22 partners, focused on life sciences regulatory matters across the U.S., UK, Belgium, the Netherlands, and China. In joining the firm, Fabien said: “I am excited to join Arnold & Porter as a partner in Brussels and to contribute to the firm’s growing life sciences and regulatory practice. With the evolving EU regulatory landscape—particularly in medical devices, pharma, digital health, and AI, clients need strategic, technically robust, and business-oriented advice. Arnold & Porter offers an outstanding platform to deliver that support at both the EU and international levels.” Fabien holds a Master Degree on European Laws, with merit, from Université de Rennes 1 and a Master of Public Law from the University of Silesia (Poland). About Arnold & Porter Arnold & Porter combines sophisticated regulatory, litigation, and transactional capabilities to resolve clients’ most complex issues. With over 1,000 lawyers practicing in 16 offices worldwide, we offer an integrated approach that spans more than 40 practice areas. Through multidisciplinary collaboration and focused industry experience, we provide innovative and effective solutions to mitigate risks, address challenges, and achieve successful outcomes.

30 December 2025 Walkers, the international legal and professional services firm, has advised InSilico Medicine Cayman TopCo ("InSilico Medicine"), a reputable AI-driven biotechnology company with global operations, on its successful IPO on the Main Board of the Hong Kong Stock Exchange ("HKEX"), backed by 15 cornerstone investors including Eli Lilly, Tencent and Temasek. The Walkers team, led by partners Andrew Barker and Mark Cummings, and supported by senior associates Beverly Lui and Flora Lo, and associate Samantha Currie, advised on all the Cayman Islands legal aspect of the transaction. The team worked closely with InSilico Medicine's lead counsel Davis Polk & Wardwell to ensure seamless execution across multiple jurisdictions. Accelerating innovation and industry development This listing underscores the development trends in emerging sectors such as AI and biotechnology. It enables InSilico Medicine to advance its clinical pipeline through its proprietary Pharm.ai platform and to invest further in cutting-edge technologies, including generative AI and automated laboratories. InSilico Medicine raised HK$2.277 billion in this IPO, achieving the largest biotech IPO in Hong Kong this year, as in the size of fundraising. Guiding clients through complex, multi-jurisdictional transactions Andrew Barker commented, 'We are proud to have provided ongoing support to InSilico Medicine, particularly in helping it reach this milestone transaction. It highlights investor confidence in emerging sectors and demonstrates our ability to deliver strategic, multi-jurisdictional legal solutions that empower clients to scale globally. Mark Cummings added, 'Our cross-border Corporate team thrives on guiding clients through complex corporate transactions. This successful listing reinforces Walkers’ commitment to delivering innovative, round-the-clock legal advice that helps businesses navigate uncharted waters and seize opportunities in dynamic markets.' Congratulations to everyone involved in this transaction. ENDS ___________________________________________ About Walkers Walkers is a leading international legal and professional services law firm specialising in the law of the global investment hubs Bermuda, BVI, Cayman Islands, Guernsey, Ireland and Jersey. With 10 strategically located offices across the Americas, Asia and Europe and 12 global practice groups, we provide seamless, multi-jurisdictional solutions to financial institutions, capital markets participants, investment fund managers, multinational corporations and family offices. Alongside Walkers' legal offering, we provide corporate and fiduciary services to many of the world's leading private equity and hedge funds, CLO managers, trusts and other financial institutions through Walkers Professional Services (WPS). For more information, contact: Shana Ray Head of Business Development, Asia & Middle East T: +852 9030 6084 E: [email protected]   Jenny Kokolas Communications Manager, Global T +44 (0)7301 272 247 E [email protected]